The role of the DNA damage response in the development and therapeutic sensitivity of malignant testicular germ cell tumors.
Project Number5F30CA247458-06
Contact PI/Project LeaderLOEHR, AMANDA
Awardee OrganizationCORNELL UNIVERSITY
Description
Abstract Text
Project Summary
Testicular germ cell tumors (TGCTs) are exceptionally sensitive to conventional genotoxic chemotherapy. This
is likely due to the distinct DNA damage response (DDR) features of TGCTs and the germ cells from which they
arise. Unlike somatic cells which often respond to DNA damage by arresting the cell cycle and conducting DNA
repair, germ cells as well as long-lived pluripotent stem cells typically avoid the use of error-prone repair
mechanisms and favor apoptosis, reducing the risk of genetic alterations in subsequent generations. Similarly,
the TGCT precursor lesion, germ cell neoplasia in situ, does not show activation of a DDR, whereas precursor
lesions of most somatic cancers express markers of an activated DDR in response to oncogene activation which
serves as a barrier to tumor progression. To study TGCTs, our lab has developed the first genetically engineered
mouse model of malignant TGCTs by conditional activation of Kras, an oncogene, and inactivation of Pten, a
tumor suppressor gene, in germ cells. The malignant teratocarcinomas generated in these mice are composed
of pluripotent embryonal carcinoma (EC) and differentiated teratoma tissue. Interestingly, EC cells, both in vivo
and cultured in vitro, express stem cell markers, have tumor propagating activity, and are readily killed following
chemotherapy treatment. Using cells derived from this model, the experiments proposed here will elucidate the
DDR properties of TGCTs and the cells from which they arise, which will inform the mechanisms underlying their
exceptional chemosensitivity. Specifically, this proposal aims to: understand how the cells that give rise to
TGCTs respond to oncogenic events, apparently avoiding DDR activation (Aim 1), and determine the mechanism
underlying the chemosensitivity of the embryonal carcinoma components of TGCTs and the chemoresistance of
their differentiated counterparts (Aim 2). Aim 1 will be investigated by generating primordial germ cell-like cells
(PGCLCs) and embryonic germ cell-like cells (EGCLCs) from induced pluripotent stem cells (iPSCs) derived
from mouse embryonic fibroblasts (MEFs) with conditional Pten and Kras alleles and assessing malignant
transformation, the degree of DNA replication stress, the extent of DNA damage, and the nature of the DDR in
untransformed and transformed cells. For Aim 2, I will analyze differential gene expression in EC and
differentiated cells before and after treatment with genotoxic chemotherapy and investigate the role of
differentially regulated pathways in the chemosensitivity phenotype. It is critically important to study this curable
cancer because understanding the basis of TGCT chemosensitivity will apply broadly to the development of
treatments for the many other cancers that do not respond favorably to conventional chemotherapy. Additionally,
understanding the malignant transformation of pluripotent cell types, including embryonic germ cells and iPSCs,
will be important for the improvement of stem-cell based therapies, which carry the risk of tumorgenicity.
Public Health Relevance Statement
Project Narrative
This proposal will elucidate the DNA damage response properties of testicular germ cell tumors (TGCTs) and
the cells from which they arise, which will inform the mechanisms underlying their remarkable sensitivity to
conventional genotoxic chemotherapy. Understanding the basis of TGCT chemosensitivity will apply broadly to
the development of treatments for the many other cancers that do not respond favorably to chemotherapy.
Additionally, investigating the malignant transformation of pluripotent cells will be important for improving stem-
cell based therapies, which carry the risk of tumorgenicity.
No Sub Projects information available for 5F30CA247458-06
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5F30CA247458-06
Patents
No Patents information available for 5F30CA247458-06
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5F30CA247458-06
Clinical Studies
No Clinical Studies information available for 5F30CA247458-06
News and More
Related News Releases
No news release information available for 5F30CA247458-06
History
No Historical information available for 5F30CA247458-06
Similar Projects
No Similar Projects information available for 5F30CA247458-06